SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Report on Form 6-K dated January 9, 2004 (Commission File No. 1-15024) ----------------- Novartis AG (Name of Registrant) ----------------- Lichtstrasse 35 4056 Basel Switzerland ----------------- (Address of Principal Executive Offices) ----------------- Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F: |X| Form 40-F: |_| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes: |_| No: |X| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes: |_| No: |X| Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes: |_| No: |X| Enclosure: Invitation to Participate in Novartis' Full Year Results 2003 Presentation. Investor Relations Novartis International AG CH-4002 Basel Switzerland [GRAPHIC OMITTED] Novartis Corporation 608 Fifth Avenue New York, NY 10020 USA -------------------------------- -SAVE THE DATE- -------------------------------- Novartis' Full Year Results 2003 Presentation to be held in Zurich, Switzerland on Thursday, January 22, 2004 Door opening at 13.30, start at 14:00 # # # -------------------------------------------------------- ---------------------------------------------- Novartis Global Investor Relations -------------------------------------------------------- ---------------------------------------------- Karen J. Huebscher, Ph.D. +41 61 324 84 33 -------------------------------------------------------- ---------------------------------------------- International office North American office Nafida Bendali +41 61 324 35 14 Alex Kelly +1 212 830 24 45 Katharina Furrer +41 61 324 53 16 John Menditto +1 212 830 24 44 Silke Zentner +41 61 324 86 12 Sabine Moravi +1 212 830 24 56 Jill Pozarek +1 212 830 24 45 e-mail: investor.relations@group.novartis.com e-mail: investor.relations@group.novartis.com Fax: +41 61 324 84 44 Fax: +1 212 830 24 05 www.novartis.com www.novartis.com -------------------------------------------------------- ---------------------------------------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Novartis AG has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NOVARTIS AG Date: January 9, 2004 By: /s/ MALCOLM CHEETHAM ----------------------------- Name: Malcolm Cheetham Title: Head Group Financial Reporting and Accounting